Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients-Reference-Cited by-同舟云学术

Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients

Published:2017-05 Issue:20 Volume:96 Page:e6931
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Zick Aviad,Peretz Tamar,Lotem Michal,Hubert Ayala,Katz Daniela,Temper Mark,Rottenberg Yakir,Uziely Beatrice,Nechushtan Hovav,Meirovitz Amichai,Sonnenblick Amir,Sapir Eli,Edelman David,Goldberg Yael,Lossos Alexander,Rosenberg Shai,Fried Iris,Finklstein Ruth,Pikarsky Eli,Goldshmidt Hanoch

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference88 articles.

1. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups;Curtis;Nature,2012

2. Comprehensive molecular portraits of human breast tumours;Cancer Genome Atlas;Nature,2012

3. The mutational landscape of lethal castration-resistant prostate cancer;Grasso;Nature,2012

4. Comprehensive molecular characterization of human colon and rectal cancer.;Nature,2012

5. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies;Lipson;Nat Med,2012

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Whole-genome sequencing and gene network modules predict gemcitabine/carboplatin-induced myelosuppression in non-small cell lung cancer patients;npj Systems Biology and Applications;2020-08-24

2. Ev vivo organ culture as potential prioritization tool for breast cancer targeted therapy;Cancer Biology & Therapy;2018-04-13

3. Defects in homologous recombination repair genes are associated with good prognosis and clinical sensitivity to DNA-damaging agents in pancreatic cancer: A case report;Molecular and Clinical Oncology;2018-03-09